Asfotase Alfa API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Asfotase Alfa API 1174277-80-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Asfotase Alfa. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Asfotase Alfa
- Synonyms:
- Asfotase alpha
- Cas Number:
- 1174277-80-5
- DrugBank number:
- DB09105
- Unique Ingredient Identifier:
- Z633861EIM
About Asfotase Alfa
Want to know more about Asfotase alfa? Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skeletal disease is obvious at birth. By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels and improve the body's ability to mineralize bone, thereby preventing serious skeletal and systemic patient morbidity and premature death. Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved by the USA Food and Drug Administration (FDA) on October 23, 2015.
Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc. The annual average price of Asfotase Alfa treatment is $285,000.
Not sure if this is the exact product you're looking for? Contact the supplier by using the send inquiry button.
